Does Methotrexate Absorption Change with Age?
Methotrexate absorption varies little with age in adults. Oral bioavailability remains consistent across age groups, typically ranging from 60-90% at low doses (under 30 mg/m2), with no significant decline in elderly patients.[1][2] Pediatric studies show similar patterns, though younger children may have slightly higher absorption due to faster gastric emptying.[3]
Why Absorption Stays Mostly Stable
Methotrexate uses carrier-mediated transport in the gut, not passive diffusion, which limits age-related impacts from reduced gut surface area or blood flow in older adults. Geriatric pharmacokinetic data confirm peak plasma levels and area under the curve (AUC) match younger adults after equivalent doses.[1][4] Food can reduce absorption by up to 20% regardless of age, but this effect does not worsen with aging.[2]
Differences in Children vs. Adults
Infants and young children absorb methotrexate faster, with time to peak concentration (Tmax) as low as 0.5-1 hour versus 1-2 hours in adults. This ties to higher intestinal motility early in life. By adolescence, absorption normalizes to adult levels.[3][5]
How Age Impacts Overall Methotrexate Handling Beyond Absorption
While absorption holds steady, age alters clearance and dosing needs:
- Elderly: Reduced renal function lowers clearance by 20-40%, raising toxicity risk; doses often cut 25-50%.[1][4]
- Children: Higher clearance requires weight- or body surface area-based dosing to avoid underdosing.[3][5]
Liver metabolism via folylpolyglutamate synthase also slows slightly in the elderly, prolonging effects.[2]
Clinical Dosing Adjustments by Age Group
| Age Group | Typical Oral Dose Adjustment | Key Monitoring |
|-----------|------------------------------|---------------|
| Children (<12 years) | 5-15 mg/m² weekly, BSA-based | CBC, liver enzymes weekly initially |
| Adults (18-65) | 7.5-25 mg weekly | Renal function, folate supplementation |
| Elderly (>65) | Start at 50% adult dose, titrate | eGFR <60 mL/min: halve dose further[1][4] |
Patient Risks and Monitoring Concerns
Older patients face higher rates of myelosuppression and mucositis due to cumulative exposure from slower elimination, not poor absorption. Guidelines recommend baseline creatinine clearance and monthly checks.[4][6] No absorption-specific tests exist; therapeutic drug monitoring focuses on plasma levels 24-48 hours post-dose.
[1]: Pharmacokinetics of Methotrexate in Elderly Patients
[2]: Oral Methotrexate Bioavailability Review
[3]: Pediatric Methotrexate Pharmacokinetics
[4]: ACR Guidelines for Rheumatoid Arthritis (Methotrexate Section)
[5]: Methotrexate in Pediatric Oncology
[6]: FDA Methotrexate Label